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Members of the Acinetobacter baumannii complex have emerged
as some of the most important opportunistic pathogens within
the hospital environment, being able to colonize and produce
infections in most immunocompromised patients, especially in
intensive care units (ICUs). Such infections are difficult to treat
due to their multiple resistance to the antibiotics currently
available for the treatment of nosocomial infections [1]. Various
mechanisms of resistance to b-lactams have been identified in
this genus, including b-lactamase production, alteration of
penicillin-binding proteins, and reduced levels of penetration
across the outer membrane.
b-Lactamase production is one of the main mechanisms of
resistance to b-lactams in Acinetobacter spp. [2,3]. Such enzymes
can be either plasmid-encoded penicillinases (TEM and CARB
type) or chromosomal cephalosporinases. The exact nature and
character of these latter enzymes are not fully clarified for
Acinetobacter spp. They belong to the group 1 b-lactamases of
the classification of Bush et al [4], but several authors have found
heterogeneity among the Acinetobacter cephalosporinases [5,6].
In the present work, the cephalosporinases produced by 125
strains belonging to the A. baumannii complex were character-
ized by determination of their pI values, b-lactamase inhibition
profiles and substrate profiles.
Clinical isolates (N¼ 125) belonging to the A. baumannii
complex, obtained in the Hospital de la Princesa (Madrid,
Spain) from January 1995 to December 1997, were studied.
The isolates were identified by the API 20NE system (BioMer-
ieux, Lyon, France) and growth at 44 8C [7]. Minimal inhibi-
tory concentrations (MICs) and susceptibility percentages of 15
b-lactam agents were determined by an agar dilution method, as
recommended by the National Committee for Clinical Labora-
tory Standards [8]. A. baumannii ATCC 19606, Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were
used as reference strains. b-Lactamase activity was detected in
crude enzymatic extracts by the hydrolysis of nitrocefin
(0.5 mg/mL). The pI values were determined by isoelectric
focusing (IEF) (Multhiphor II Electrophoresis System; Amer-
sham Pharmacia Biotech, Uppsala, Sweden), on wide-range
ampholine (pH range 3.5–9.5) polyacrylamide gels; in some
cases a narrow-range ampholine (pH 5.5–8.5) was used.
The percentage of inhibition of the following inhibitors was
studied at fixed concentrations for 43 enzymatic extracts:
clavulanic acid (10 mM), sulbactam (20 mM), cloxacillin
(4 mg/mL), aztreonam (1.148 mM), NaCl (140 mM) and EDTA
(0.1 mM). This assay was performed as described by Papani-
colaou et al [9] with several modifications. After incubating the
extracts with nitrocefin solution, the changes in optical density
at a wavelength of 492 nm were measured at 2, 5 and 10 min,
and subsequently at 10-min intervals for 40 min. Duplicate
determinations were performed for each extract.
Sixteen crude enzymatic extracts were selected to study the
substrate profile of the b-lactamases. Two methods were used.
First, hydrolysis of the following b-lactams by the crude extracts
was studied with a microbiological assay as described by Paton
et al [10]: ampicillin, cefazolin, oxacillin, carbenicillin, cefur-
oxime, cefotaxime, ceftazidime, imipenem and meropenem.
OXA-2 and TEM-1 were used as control enzymatic extracts.
Staphylococcus aureus ATCC 25923 and E. coli ATCC 25922
were used as hydrolysis control strains depending on the anti-
biotic tested. Second, assay UV spectrophotometry was used to
study the hydrolysis rate of cephaloridine, benzylpenicillin,
cefotaxime, ceftazidime, imipenem, meropenem, carbenicillin
and oxacillin. Duplicate determinations were performed for
each enzymatic extract, with concentrations of either 100 mM
or 1 mM. Hydrolysis rates were expressed as a percentage of
hydrolysis with respect to cephaloridine.
A high percentage of susceptibility was found to imipenem,
meropenem and ampicillin–sulbactam (100%, 100% and 84%,
respectively); however, low susceptibility was shown to most
penicillins (piperacillin, 8%; ticarcillin, 18.4%), and cephalos-
porins (cefotaxime, 4.8%; ceftazidime, 11.2%; cefepime,
12.8%). Isoelectric focusing showed a unique band of pI> 8
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in all the enzymatic extracts tested. When a narrower range of
ampholines (5.5–8.5) was used, two different pI groups of>8.5
and between 8 and 8.5 were observed. The b-lactamases (72%)
with a pI of >8.5 were designated pI group I, while the
b-lactamases (28%) with a pI between 8 and 8.5 were designated
pI group II.
Maximum inhibition of these enzymes by inhibitors was
usually observed after 2 min, but occasionally after 5 min. All of
the enzymes showed a maximum percentage of inhibition with
clavulanic acid of <45%. All were inhibited (80–90%) by
sulbactam, cloxacillin and aztreonam. The values with NaCl
and EDTA were<30% for all enzymes. Examples of inhibition
profiles of these enzymes, expressed as an average of the
maximum percentage of inhibition, are shown in Table 1.
Hydrolysis of ampicillin, cefazolin, cefuroxime and cefotax-
ime could be demonstrated by a microbiological assay for all
enzymatic extracts, but this test was negative for ceftazidime,
carbenicillin, imipenem and meropenem. Cephaloridine
hydrolysis was observed by spectrophotometric assay at con-
centrations of 100mM with most b-lactamase extracts, but a
concentration of 1 mM was needed to demonstrate hydrolysis
with some extracts. Examples of the hydrolysis rates observed
are shown in Table 2, expressed as the hydrolysis rate with
respect to cephaloridine. Significant hydrolysis of cefotaxime,
ceftazidime, carbenicillin, imipenem and meropenem could not
be demonstrated by this method.
Cephalosporinases are considered to play a significant role in
resistance to cephalosporins in Acinetobacter spp. Morohoshi, in
1977, reported a b-lactamase from Acinetobacter anitratus (syn.
calcoaceticus) with a pI of 7.25–7.5, which was not inhibited by
clavulanic acid or EDTA, and which was included in group 1
(CEP-N) of the classification of b-lactamases [11]. A new
cephalosporinase, with a pI of 9.9, was characterized by Hikida
et al [12]. Blechschmidt in 1992 [13] demonstrated clear
inhibition of the same enzyme by cloxacillin, aztreonam,
carbenicillin and sulbactam. There was no inhibition by cla-
vulanic acid at concentrations up to 0.25 mM, nor by EDTA or
pCMB. This b-lactamase was also included in the CEP-N
group of cephalosporinases.
Cephalosporinases belonging to group 1 are well inhibited by
cloxacillin and aztreonam but are not inhibited by clavulanic
acid. Cephalosporinases from Acinetobacter are also inhibited by
sulbactam, suggesting the inclusion of these enzymes in group
2d, but these enzymes are also inhibited by pCMB. Inhibition
by sulbactam has only been observed for cephalosporinases from
Acinetobacter spp. and in a Citrobacter freundii isolate [14]. The125
isolates in the present study seemed to possess cephalosporinases
from group 1 of the classification of b-lactamases [15], since
Table1 Average percentage of inhibition for selected chromosomal b-lactamases found in isolates belonging to theA. baumannii complex
Individual strain pI group Clavulanic acid Cloxacillin Sulbactam Aztreonam EDTA NaCl
44 I 15 93.6 83.8 93.2 16.5 19.8
86 II 18.2 93.4 87.7 92.9 15.5 36
90 I 20 94 82 94 11.6 10
32 I 11.5 93.4 88.4 93.9 12 16
55 II 10 90.4 91.4 91.4 15.9 15.9
144 II 42.8 93.7 90.8 94.8 10.8 14.4
50 I 8.9 82 80.4 88.8 18.4 15
98 I 13.6 96.3 82.1 94.2 10.8 14.4
107 II 12.8 94.4 87.2 95 11.6 15.8
pI group I>8.5; pI group II 8^8.5.
Table2 Examples of relative hydrolysis rates for chromosomal b-lactamases from isolates belonging to the A. baumannii complex
Individual strain pI group Cephaloridine Penicillin Cefotaxime Ceftazidime Carbenicillin Imipenem Meropenem
44 I 100a 17.3 <0.03 <0.003 11.2 0.24 0.34
90 I 100a 9.4 0.14 <0.003 <11.2 0.07 0.14
32 I 100a 6.2 0.03 0.003 <11.2 0.06 0.1
55 II 100 31.8 3.7 1.5 <11.2 0.47 1.1
86 II 100a 16.7 1 0.003 <11.2 3.2 2.5
144 II 100 65.3 14.6 9.2 <11.2 8 12.6
50 I 100a 12.6 2.2 0.07 <11.2 0.04 0.01
98 I 100a 15.4 0.22 0.29 <11.2 0.052 0.17
107 II 100 50 4 5 <11.2 8.7 6.2
aCephaloridine concentration of1mM.
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they were inhibited by cloxacillin, aztreonam and sulbactam,
but not by clavulanic acid.
The separation of b-lactamases from Acinetobacter by iso-
electric focusing is sometimes difficult because of their large
molecular mass and poor enzyme solubility [5]. Some authors
consider a cephalosporinase-type enzyme as having variable
bands of b-lactamase activity located at pI> 8 [16]. In the
present study, two types of cephalosporinases were character-
ized as the basis of a pI very close to the cathode (type I,
pI> 8.5), and a pI between 8 and 8.5 (type II). Hood and Amyes
[5] reported at least four different Acinetobacter cephalosporinases
on the basis of different pI values always >8. The group 1
cephalosporinases produced by three Acinetobacter spp. clinical
isolates, characterized by Perilli in 1996 [6], appeared to be
different from other group 1 b-lactamases and also from each
other. Our results confirm that there is a considerable hetero-
geneity between cephalosporinases of Acinetobacter.
The inhibitory profile assay described by Papanicolaou et al
[9] allows b-lactamases to be characterized by determining the
percentage of inhibition. The hydrolysis profile confirmed that
the b-lactamases of this study were cephalosporinases. These
enzymes hydrolyzed ampicillin, first- and second-generation
cephalosporins and cefotaxime (only demonstrated by micro-
biological assay), but not ceftazidime or carbenicillin. Hydro-
lysis rates obtained with these substrates are usually lower by
spectrophotometric assay than by other methods. Some authors
have suggested that ceftazidime is less susceptible to the action of
cephalosporinases than cefotaxime, as demonstrated in other
studies where the hydrolysis rate of ceftazidime was even lower
than the rate for cefotaxime [17,18]. Group 1 cephalosporinases
of Gram-negative bacteria are defined as having preferential
activity against cephalosporins, but are also able to efficiently
inactivate penicillins [19]. For this reason, alternative methods,
such as microbiological assay, are sometimes needed to confirm
cephalosporinase activity.
In conclusion, the A. baumannii complex isolates investigated
in this study yielded two major types of cephalosporinases,
which appeared to belong in the group 1 classification of b-
lactamases [15]. These enzymes showed heterogeneity on the
basis of their different pI values, inhibition profiles and hydro-
lysis rates with several b-lactam agents. These differences in
their biochemical behavior, as well as the relevance of these
enzymes in the antimicrobial resistance in Acinetobacter spp.,
require further detailed studies.
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